International Myeloma Foundation
Advocacy Update | August 2021
capitol hill with action center button
Pills on bills
Cancer Drug Parity Act Reintroduced
On July 9, 2021, H.R. 4385, the Cancer Drug Parity Act was reintroduced in the House of Representatives by Representatives Brian Higgins (D-NY), Brett Guthrie (R-KY), Joe Morelle (D-NY), Glenn Grothman (R-WI), Doris Matsui (D-CA) and Gus Bilirakis (R-FL). The IMF would like to thank these members for their continued leadership on this issue and for being champions for affordable access to cancer care.

The bill would protect the approximately 140 million patients covered by federally regulated group health plans by ending the preference for cancer care that is not administered orally. Orally administered anticancer medications are used to treat many cancers, including multiple myeloma. This bill would help patients with group health insurance plans access these drugs by ensuring fairness in cost-sharing for all anticancer regimens, ultimately reducing their out-of-pocket expenses.

To let the House of Representatives know you support this bill, please click HERE.
550x275capitolBuilding.jpg
Clinical Trials Bill Introduced
On August 13, 2021, Senator Bob Menendez (D-NJ), Senator Tim Scott (R-SC), Rep. Raul Ruiz (D-CA), and Rep. Larry Bucshon (R-IN) introduced H.R. 5030/S. 2706 the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act.

The lack of racial and ethnic diversity among clinical trial participants has been a persistent problem that this bill aims to address. According to Sen. Menendez’s office, “Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Act would allow the U.S. Department of Health and Human Services (HHS) to issue grants or enter into contractual arrangements to support education, outreach and recruitment for clinical trials for diseases with disproportionate impact on underrepresented populations.”

The IMF thanks these members for taking the lead on this important issue. It is critical that patients enrolled in clinical trials reflect the populations who will ultimately be taking the drug. To learn more about this legislation, please click HERE.
medicare b on paper
Most Favored Nation Rule Rescinded
On Friday, August 6, 2021, The Biden Administration announced that they would be rescinding the controversial most favored nations proposed rule.

As background, this proposal would have tied Medicare Part B drug prices to the prices paid in foreign countries with economic situations similar to the United States’. Those in favor of this proposal believed it would reduce prices however, there were also concerns that it could negatively impact patient access to some treatments.
 

Want to get involved?

Interested in learning more or taking actions about our federal and/or state priorities? Email the IMF Advocacy Team, advocacy@myeloma.org, to find out ways you can help and make your voice heard. Find us on the Twitter and Facebook! We will be sharing the latest news on legislation and policies we are tracking. And follow @Chemoparity for updates on our fight to get oral parity passed at the state and federal levels.
Get_Involved.png
 

We Thank Our Sponsor:

Bristol-Myers Squibb
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter: @IMFMyeloma  |  Instagram Instagram: @IMFmyeloma

www.myeloma.org
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page